RXi Replaces CEO

Luke Timmerman11/6/09

RXi Pharmaceuticals (NASDAQ: RXII), the Worcester, MA-based developer of RNA interference drugs, said today that Noah Beerman has replaced Tod Woolf as president and CEO. Beerman, 47, was most recently chief business officer of Indevus Pharmaceuticals. The company said the leadership switch was part of a succession plan as it looks to advance into product development. Woolf will remain on the company’s scientific advisory board.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.